<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations/><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/52D857EC-7082-4AF9-8BCA-0722703573E7"><gtr:id>52D857EC-7082-4AF9-8BCA-0722703573E7</gtr:id><gtr:name>Lif Nano Rx Ltd</gtr:name><gtr:address><gtr:line1>10 FENDON ROAD</gtr:line1><gtr:city>CAMBRIDGE</gtr:city><gtr:postCode>CB1 7RT</gtr:postCode><gtr:region>East of England</gtr:region></gtr:address><gtr:typeInd>P</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/52D857EC-7082-4AF9-8BCA-0722703573E7" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="gtr:organisationParticipantRole"><gtr:id>52D857EC-7082-4AF9-8BCA-0722703573E7</gtr:id><gtr:name>Lif Nano Rx Ltd</gtr:name><gtr:address><gtr:line1>10 FENDON ROAD</gtr:line1><gtr:city>CAMBRIDGE</gtr:city><gtr:postCode>CB1 7RT</gtr:postCode><gtr:region>East of England</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_PARTICIPANT</gtr:name></gtr:role><gtr:role><gtr:name>PARTICIPANT</gtr:name></gtr:role></gtr:roles><gtr:offerGrant>174998.0</gtr:offerGrant><gtr:projectCost>249997.0</gtr:projectCost></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/D5337A10-AC8A-402A-8164-C5F9CC6B0140" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="gtr:organisationParticipantRole"><gtr:id>D5337A10-AC8A-402A-8164-C5F9CC6B0140</gtr:id><gtr:name>Queen Mary, University of London</gtr:name><gtr:address><gtr:line1>Mile End Road</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>E1 4NS</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>PARTICIPANT</gtr:name></gtr:role></gtr:roles><gtr:offerGrant>39231.0</gtr:offerGrant><gtr:projectCost>39231.0</gtr:projectCost></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/A40B05D5-27FA-4B57-84A3-3A31B4A08087" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="gtr:organisationParticipantRole"><gtr:id>A40B05D5-27FA-4B57-84A3-3A31B4A08087</gtr:id><gtr:name>Centre for Process Innovation Limited</gtr:name><gtr:address><gtr:line1>WILTON CENTRE , WILTON,</gtr:line1><gtr:city>REDCAR</gtr:city><gtr:postCode>TS10 4RF</gtr:postCode><gtr:region>North East</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>PARTICIPANT</gtr:name></gtr:role></gtr:roles><gtr:offerGrant>386875.0</gtr:offerGrant><gtr:projectCost>386875.0</gtr:projectCost></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/8A0E4443-659B-47A4-9179-BBC2A45BD5F5" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="gtr:organisationParticipantRole"><gtr:id>8A0E4443-659B-47A4-9179-BBC2A45BD5F5</gtr:id><gtr:name>Pharmidex Pharmaceutical Services Limited</gtr:name><gtr:address><gtr:line1>3RD FLOOR , 14 HANOVER STREET</gtr:line1><gtr:city>LONDON</gtr:city><gtr:postCode>W1S 1YH</gtr:postCode><gtr:region>London</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>PARTICIPANT</gtr:name></gtr:role></gtr:roles><gtr:offerGrant>227523.0</gtr:offerGrant><gtr:projectCost>325033.0</gtr:projectCost></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/B9358043-B794-44AB-950C-34D41F82A859"><gtr:id>B9358043-B794-44AB-950C-34D41F82A859</gtr:id><gtr:firstName>Alan</gtr:firstName><gtr:surname>Clark</gtr:surname><gtr:roles><gtr:role><gtr:name>PROJECT_MANAGER</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=102847"><gtr:id>A18907D1-7758-4AC5-AA70-2F641BC7014A</gtr:id><gtr:title>CELL-FREE REGENERATIVE MEDICINE: Nano-Engineered &amp;quot;LIFNano&amp;quot; to treat Multiple Sclerosis</gtr:title><gtr:status>Active</gtr:status><gtr:grantCategory>Collaborative R&amp;D</gtr:grantCategory><gtr:grantReference>102847</gtr:grantReference><gtr:abstractText>NANOMEDICINE (NanoMed) is a new era in medicine that exploits nano-engineering to deliver the right dose of therapy to the right place, at the right time. LIF is a growth factor important for maintaining brain health and the SME &amp;quot;LNT&amp;quot; has pioneered NanoMed for delivery of LIF as a revolutionary approach to treat the devastating autoimmune disease MULTIPLE SCLEROSIS (MS). Incurable, MS attacks the brain, starting in young adulthood and costing the global economy some $100bn pa. AIMS: having proven LIFNano (LN001) is far superior to the best alternative therapy for MS, this project will now deliver LN001 to patients on two fronts: (i) by establishing the first UK-based commercial resource for NanoMed; and (ii) by securing LN001 in a clinical formula. Three levels of synergy operate: UK manufacture, UK intellectual property with worldwide exclusive licence to LNT, and UK-based global leader in new therapeutic approaches to MS. The gain to the UK economy will be high and the added value of I-UK support to LNT will exceed 100-fold on licencing as Big Pharma become engaged especially since LN001 is applicable to a wide range of degenerative conditions. Further added value is in the increased specialist portfolio of UK's High Value Manufacturing Catapult (CPI).</gtr:abstractText><gtr:fund><gtr:end>2018-12-31</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/E18E2F0F-AC7D-4E02-9559-669F7C8FEC74"><gtr:id>E18E2F0F-AC7D-4E02-9559-669F7C8FEC74</gtr:id><gtr:name>Innovate UK</gtr:name></gtr:funder><gtr:start>2017-01-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>828627</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs/><gtr:disseminationOutputs/><gtr:exploitationOutputs/><gtr:furtherFundingOutputs/><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications/><gtr:identifiers><gtr:identifier type="RCUK">102847</gtr:identifier></gtr:identifiers><gtr:healthCategories/><gtr:researchActivities/><gtr:researchSubjects/><gtr:researchTopics><gtr:researchTopic><gtr:id>D05BC2E0-0345-4A3F-8C3F-775BC42A0819</gtr:id><gtr:text>Unclassified</gtr:text></gtr:researchTopic></gtr:researchTopics><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>